About
Viritis is a biotech company pioneering a next-generation antisense-based platform for rapid development of antiviral drugs. Our novel technology targets all strains of a given virus, offering a scalable and precise solution for current and emerging viral threats. Our platform combines AI-driven algorithms with patented molecule design to bind specifically to viral RNA. Once attached, it activates the cell’s innate defense mechanisms, degrading the virus from within— without harming the host. After completing its function, the molecule naturally disintegrates within hours, leaving no harmful residues. In POC studies, our platform demonstrated 97.1% cellular protection against the target virus. Its innovative structure also makes it highly stable, can be lyophilize, and easy to store and transport—ideal for global deployment.
Funding history · 3 rounds · $665K total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Viritis's core technology for antiviral drug development?
- Viritis is developing a next-generation antisense-based platform that uses AI-driven algorithms and patented molecule design to target and degrade viral RNA within cells, without harming the host. The molecules naturally disintegrate within hours.
- When was Viritis founded and where is its headquarters located?
- Viritis was founded in August 2020 and is headquartered in Petah Tikva, Israel.
- What was Viritis's most recent funding round, and who was a lead investor?
- In February 2025, Viritis completed a Pre-Seed funding round, with Road2 participating as an investor. For full financing history, refer to startupim.
- How much grant funding has Viritis received and from which organization?
- In February 2025, Viritis received a grant of $500,000 from the IIA (Israel Innovation Authority).
- What is the name of Viritis's innovative antiviral molecule?
- Viritis's innovative antiviral molecule is named EXHAUVIR.
- What was a key finding from Viritis's Proof of Concept (POC) studies?
- In POC studies, Viritis's platform demonstrated 97.1% cellular protection against the target virus.
- How many employees does Viritis currently have?
- Viritis currently has 4 employees.
- What is Viritis's primary sector and target customer base?
- Viritis's primary sector is Health Tech & Life Sciences, and its target customers include the Biotechnology and Pharmaceutical industries.